Plain-language · Issue 4 · 2026-10-15
ETI-Era Therapy De-escalation: Real-World Data Suggest Short-Term Safety, But Important Gaps Remain
Editorially reviewed research summaries, context, and limitations.
Cynthia D Brown, Kevin J Psoter, Kathryn A Sabadosa, et al.
Summary: This study — called HERO-2 — followed 709 people with CF aged 12 and older who were taking ETI, over a period of 12 months. It asked whether people who stopped one or more of their other daily CF treatments — such as airway clearance devices, inhaled antibiotics, or mucus-thinning medicines — had worse lung outcomes than those who kept taking everything. Using a statistical method to account for differences between the groups, the researchers found no significant increase in lung infections or lung function decline among those who had stopped some treatments. Notably, 41.5% of participants had already stopped at least one such treatment on their own before the study began.
Why it matters: ETI has improved health so much for many people with CF that patients and their doctors are asking a natural question: does everyone still need to take all of their other treatments every day? These treatments are time-consuming, burdensome, and expensive. The HERO-2 study is the first to follow people prospectively — tracking them forward in time — to see what happens when some treatments are stopped. The finding that stopping did not appear harmful over 12 months is useful for conversations between patients and their care teams, even though it does not amount to a green light for everyone to start stopping therapies.
What to keep in mind: The study has important limitations to consider. People reported which treatments they had stopped through an app, so the details — exactly which treatments, when they stopped, and how consistently — are not fully known. Twelve months may not be long enough to detect gradual lung decline, particularly in people who are doing well on ETI. People who felt well enough to stop treatments may have been healthier to begin with, and no statistical method can fully account for that. The group studied was recruited through a digital platform, which may not represent people with more severe disease or less access to technology. The study does not prove that stopping treatments is safe — it shows that in this group, over this period, no clear harm was detected. That is a meaningful finding, but more research with longer follow-up and better detail about which treatments are stopped is needed before any broad recommendations can be made.
Relevance: Cystic Fibrosis
Source: https://pubmed.ncbi.nlm.nih.gov/42554296/
---